Genexin

Quick links to important sections

Genexin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Genexin

What is Genexin?

Genexin is a standardized herbal extract derived from the leaves of the Ginkgo biloba tree. It is classified as a cognitive enhancer and peripheral vasodilator, utilized primarily to support circulatory function and metabolic processes within the central nervous system.

Composition and Mechanism

The extract contains a specific ratio of active compounds, primarily flavonoid glycosides and terpene lactones (such as ginkgolides and bilobalide). These components work through several physiological pathways:

  • Vasodilation: It helps improve blood flow by reducing blood viscosity and regulating the tone of blood vessels.
  • Antioxidant Activity: It acts as a scavenger for free radicals, helping to protect cells and tissues from oxidative stress.
  • Neuroprotection: It supports neuronal metabolism, potentially helping to maintain cognitive functions such as memory and concentration.

Primary Uses

Genexin is most commonly used in the management of symptoms related to impaired cerebral circulation and age-related cognitive decline. This includes conditions where patients experience a decrease in intellectual performance, such as concentration difficulties or memory loss.

Additionally, it is used to address symptoms associated with peripheral arterial circulatory disturbances. This includes help with circulation-related issues in the extremities, as well as certain inner ear or equilibrium disorders, such as vertigo or tinnitus, when these are suspected to be of vascular origin.

What side effects are possible with Genexin?

Possible Side Effects and Safety Information

Genexin (Venlafaxine Hydrochloride) has an officially documented safety profile based on clinical trials and regulatory surveillance. Adverse reactions are classified by frequency and grouped into System-Organ Classes as defined by governmental health authorities.


Officially Classified Adverse Reactions

The most frequently reported reactions are classified as common in official labeling. These include effects on the Gastrointestinal System, such as nausea, dry mouth, and constipation, as well as sweating (hyperhidrosis). Nervous system effects like somnolence (drowsiness) and dizziness are also common. Effects on the Reproductive System, including decreased libido and abnormal ejaculation in men, are documented as common

.


Serious Safety Concerns and Warnings

Regulatory documents highlight several serious safety concerns. These include a warning regarding the risk of Suicidal Thoughts and Behaviors, particularly in young adults (ages 18–24). A potentially life-threatening reaction known as Serotonin Syndrome is a documented risk, especially when Genexin is used with other agents that affect serotonin. The drug is associated with the potential for elevated blood pressure and may increase the risk of Abnormal Bleeding events.


Population and Time-Related Safety Patterns

The official labeling specifies constraints for certain patient groups. The medication is not approved for pediatric patients. Clearance is reduced in individuals with significant hepatic or renal impairment. The risk of Serotonin Syndrome is greatest during treatment initiation and following dose increases. Symptoms related to discontinuation syndrome may occur upon abrupt cessation or dose reduction.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Genexin (Venlafaxine) is a serious event that primarily affects the central nervous system (CNS) and the cardiovascular system, according to official regulatory documentation. Management is strictly supportive, as no specific pharmacological antidote is known for this compound.

Documented Clinical Manifestations

Official labels document that an overdose may present with a cluster of severe symptoms, including changes in mental status (ranging from confusion and agitation to coma), seizures (convulsions), tachycardia (rapid heart rate), and labile blood pressure (high or low). Other documented signs include mydriasis (enlarged pupils), hyperthermia (fever), and symptoms related to neuromuscular overactivity, such as muscle rigidity and twitching.

Severe Outcomes and Required Actions

Regulatory documents explicitly classify Serotonin Syndrome as a potential life-threatening outcome of Venlafaxine overdose, characterized by mental status changes, autonomic instability, and neuromuscular aberrations. Severe toxicity can also lead to cardiac conduction abnormalities, including QTc prolongation, which requires monitoring.

The official guidance states that immediate action is necessary: Get medical help right away if signs of severe symptoms or Serotonin Syndrome are noted. Users are directed to Call 911 for an emergency. Continuous cardiac monitoring and supportive treatment are required due to the documented risks.

Therapeutic Uses of Genexin

What Genexin Treats: Main Uses and Benefits

Genexin (Venlafaxine) is commonly used to treat a core group of mood and anxiety disorders in adults, addressing symptoms that interfere with daily functioning. This medication is utilized to help manage Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder, and Panic Disorder.

The medication is generally applied across therapeutic domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations. It is commonly used to help with conditions characterized by periods of heightened symptoms, specifically MDD, where it is relevant for easing symptoms that create noticeable functional strain related to persistent low mood, hopelessness, and loss of pleasure (anhedonia). It may assist with managing symptoms related to physical discomfort, such as fatigue and low energy often associated with depression.

Genexin is also applied in areas where additional symptomatic support is needed, helping address symptom clusters that may become intense or disruptive, such as chronic worry, symptoms related to heightened physiological activity, and panic attacks. This offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.


Quick Fact: Use in Managing Specific Somatic Discomforts

Genexin is considered relevant in clinical settings that involve acute or unstable symptom patterns. It is applied when appropriate for easing symptoms related to physical discomfort, such as chronic neuropathic pain (nerve-related pain), and is used for managing symptoms related to systemic imbalance, such as hot flashes. This provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Genexin (Venlafaxine)

Genexin (Venlafaxine Hydrochloride) eligibility is strictly defined by government regulatory agencies based on age, concurrent medical conditions, and organ function status.

Populations Permitted and Restricted

The medicine is officially approved for use in adult patients aged 18 years and older. Use in children and adolescents (under 18 years) is not approved and generally not recommended by regulatory bodies, as efficacy has not been established. While older adults (65 years and older) are eligible, use requires caution due to the higher likelihood of age-related decline in organ function.

Absolute Contraindications

Genexin must not be used in patients with a known hypersensitivity to venlafaxine or any component of the formulation. It is also strictly contraindicated for use in patients who are taking a Monoamine Oxidase Inhibitor (MAOI) for psychiatric treatment, or within 14 days of discontinuing an MAOI, due to the critical risk of Serotonin Syndrome.

Organ Function Restrictions

Eligibility is restricted for patients with severe renal impairment or severe hepatic impairment, as their ability to clear the drug is compromised. Use in these patients is conditional and generally limited to a substantially reduced daily dose. Furthermore, use during pregnancy, particularly the third trimester, and lactation is restricted and warranted only when potential benefits outweigh the documented risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Genexin (Venlafaxine) has officially documented interaction patterns based on metabolic pathways and pharmacodynamic effects, requiring specific administrative constraints and prohibitions.


Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic Linezolid and Intravenous Methylene Blue, is strictly contraindicated. A mandatory 14-day washout period is required after discontinuing an MAOI before Genexin can be initiated, and at least 7 days must pass after stopping Genexin before starting an MAOI.


Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agents Formal Outcome (Regulatory Description)
Metabolic Inhibition CYP3A4 Inhibitors (e.g., Ketoconazole) Increases plasma concentrations (exposure) of both venlafaxine and its active metabolite.
Serotonergic Load Other Serotonergic Drugs (e.g., Triptans, SSRIs, St. John's Wort) Increased risk of Serotonin Syndrome.
CNS Depression Alcohol, other CNS-Active Drugs Increased risk of sedation and psychomotor impairment; co-administration is not recommended.
Hemostasis Risk Drugs Affecting Hemostasis (e.g., NSAIDs, Warfarin) Increased risk of abnormal bleeding events due to effects on platelet function.

Exposure is increased in patients with hepatic or renal impairment, which may heighten the significance of pharmacokinetic interactions. Extended-release formulations should be administered with food.

Mechanism of Action

Genexin, which refers to the isoflavone genistein, exerts its pharmacodynamic effects through multiple intracellular and molecular targets. It functions as an inhibitor of various receptor tyrosine kinases (RTKs), including the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR). This inhibition directly suppresses downstream signaling cascades such as the Phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway and the Mitogen-Activated Protein Kinase (MAPK) pathway. The reduced phosphorylation of AKT results in the inactivation of its targets, including Nuclear Factor-κB (NF-κB), thus modulating the transcription of target genes.

Genexin also exhibits partial agonist and antagonist activity at estrogen receptors (ERs), binding to both ERalpha and ERbeta to competitively modulate endogenous estrogen signaling. Intracellularly, it induces cell cycle arrest by upregulating cyclin-dependent kinase inhibitors (CDKIs) like p21 and downregulating cyclins, particularly those regulating the G2-M checkpoint. Furthermore, the compound modulates the intrinsic apoptotic pathway by decreasing the Bcl-2/ Bax ratio, leading to mitochondrial membrane permeabilization and the subsequent activation of caspases.

Dosage and Administration Information

How to use Genexin: Official Administration Guidelines

Genexin is a gene therapy product requiring a single, precisely controlled administration. This medicine is administered one time only via intravenous (IV) infusion for adult patients aged 18 years and older.

Administration Scope and Procedure

Feature Official Requirement
Route of Administration Intravenous (IV) infusion
Dosing Schedule Single dose of 2 mL/kg body weight
Frequency One-time-only administration
Timing (Meals) Not specified in relation to meals

Preparation and Infusion Steps

The preparation process for Genexin involves a standardized sequence. The total, calculated dose is diluted immediately before use with 0.9% normal saline solution. The final solution must be clear and colorless upon visual inspection and must not be administered if particulates or discoloration are present. The infusion is delivered at a constant rate of 500 mL/hour and must be completed within 1 to 2 hours. The medication must not be administered as an intravenous push or bolus, and it must not be co-infused with other products in the same IV line.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Genexin


Evidence for Use in Major Depressive Disorder (MDD)

Research into the study of Genexin for MDD symptoms primarily involves multiple Randomized Controlled Trials (RCTs), including double-blind and placebo-controlled trials. These short-term trials, which typically lasted 8 to 12 weeks, evaluated outcomes measured in participants receiving Genexin against those receiving an inactive substance (placebo) or specific comparator antidepressants. Researchers monitored changes in outcomes related to persistent low mood and loss of pleasure using standardized scales. Findings describe patterns related to changes measured during the study period, helping contextualize how patients reported their experience during periods of increased symptom activity.


Evidence for Use in Generalized Anxiety Disorder (GAD)

The evidence base for studying Genexin in GAD includes Randomized Controlled Trials (RCTs), including double-blind and placebo-controlled trials. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to chronic worry and heightened physiological strain. Studies reported how symptoms evolved in the observed populations evaluated against placebo. Trials also monitored long-term recurrence, describing patterns related to outcomes for the return of GAD symptoms over periods of up to six to twelve months in participants who had previously shown a study-defined change.


Documented Evidence Gaps and Areas of Uncertainty

Despite the research conducted, certain limitations have been documented by scientific sources. Limited information for long-term outcomes that track patients for several years means the long-term effects are not fully established beyond the one-year mark in the majority of published controlled research. Data for certain groups remain insufficient, particularly for individuals with complex medical conditions alongside their primary diagnosis, as key trials often excluded these patients to isolate the outcomes. For some indications, findings were mixed across studies or were not consistently reported across all trial outcomes, meaning certainty remains low for specific endpoints. Findings reflect only the populations studied and the specific conditions under which the research was conducted.

Key Studies & References

  1. NICE Guideline NG222: Depression in adults: treatment and management
  2. NICE Guideline CG113: Generalised anxiety disorder and panic disorder in adults: management
  3. Venlafaxine versus SSRIs for treatment of major depressive disorder: a systematic review and meta-analysis of head-to-head randomized clinical trials

Frequently Asked Questions (FAQ)

Common questions about Genexin (FAQ)

Q: Are there any specific vitamins or supplements that should not be taken with Genexin?

Official prescribing information highlights an increased risk of a potentially serious condition called Serotonin Syndrome when Genexin is used alongside other agents that affect serotonin. The regulatory documents specifically name the herbal product St. John’s Wort as a supplement known to have this type of interaction. It is generally recommended to review all supplements and vitamins with a healthcare provider.

Q: What food or drink items, if any, are listed as interacting with Genexin?

Official documents describe that consuming alcohol while using Genexin can increase the risk of sedation and affect motor skills. Additionally, the drug’s extended-release (XR) formulations are specifically noted to be administered with food. This administration method is suggested to support the consistent absorption of the medicine.

Q: Are there age limits or weight restrictions mentioned for using Genexin?

Genexin is officially approved for use in adult patients aged 18 years and older. While age is a key eligibility criterion for this medicine, official regulatory documents do not list specific weight restrictions that restrict its use.

Q: Can Genexin be taken for a long time, or is it only for short-term use?

Research supporting the use of Genexin includes clinical studies that have tracked patients for periods of up to six to twelve months. Regulatory documents summarize this research and note that there is currently limited information available for outcomes that track patients for several years beyond the one-year mark.

Q: Does Genexin affect a person's ability to drive or operate machinery?

Adverse effects of Genexin that are classified as common in official safety information include dizziness and somnolence (drowsiness). These effects, as well as the potential for psychomotor impairment, may affect a person’s ability to drive, operate machinery, or perform other tasks requiring alertness.

Q: What are the key safety warnings about Genexin for people with heart conditions?

Official safety documents list the potential for sustained elevation of blood pressure as a documented risk associated with the use of Genexin. This information is included in the warnings and precautions section of the prescribing information.

Q: Does Genexin affect fertility?

Regulatory documents describe common effects on the reproductive system, such as decreased libido and abnormal ejaculation. Specific data on the drug's direct effect on fertility (the ability to conceive) is generally addressed separately from other common reproductive side effects.

Q: How long after starting Genexin should someone expect to notice a difference?

Clinical trial information summarizes findings related to the changes measured in participants receiving Genexin. These changes were generally monitored during study periods that typically lasted between 8 and 12 weeks.

Q: What should be done if a dose of Genexin is forgotten?

Patient information approved by regulatory bodies provides specific instructions for how to handle a missed dose of Genexin. Official guidance on handling a missed dose is included in the approved patient information for Genexin.

Q: Does Genexin need to be taken at a specific time of day?

Official administration guidelines detail the required dosing frequency for Genexin, such as whether it is taken once daily or multiple times daily. These guidelines may also include descriptive guidance regarding the timing of administration to support consistent drug levels.

Q: Is it normal to experience a headache when beginning Genexin?

The official regulatory list of side effects, which collects data from clinical trials, classifies the incidence of headache by its frequency (e.g., common or uncommon). This classification reflects how often headache was reported by participants during the clinical studies.

Q: Is the active ingredient in Genexin also found in other medications?

Yes. The active ingredient in Genexin is Venlafaxine Hydrochloride. This compound is available not only under the brand name Genexin but also in multiple other brand names and in generic formulations, which are listed in official government drug directories.

Q: Can Genexin affect blood sugar levels?

The official regulatory list of side effects, which tracks changes observed in clinical trials, classifies the incidence of changes in blood glucose levels. This classification reports the frequency of both elevated blood sugar (hyperglycemia) and low blood sugar (hypoglycemia) based on the collected study data.

Q: Is Genexin listed as having the potential for dependence or addiction?

Official prescribing information includes a regulatory section specifically focused on the potential for abuse and dependence for this medicine. This section addresses whether the drug has been classified as a controlled substance by government agencies.

Q: Can Genexin be crushed or split if someone has trouble swallowing pills?

Regulatory administration guidelines provide explicit constraints regarding the integrity of the tablets and extended-release capsules. These guidelines state precisely whether the solid oral forms can be crushed, split, or chewed, as these actions affect the drug's intended release mechanism.

Q: What is the difference between the generic and brand name versions of Genexin?

Regulatory agencies, such as the FDA in the U.S., confirm that generic versions of the active ingredient are considered bioequivalent to the brand-name product. This means the generic product delivers the same amount of the active compound to the bloodstream in the same amount of time as the brand-name product.

Q: Is there a maximum time frame for how long Genexin can be used?

Official administration guidelines detail the recommended duration of use for Genexin. For certain approved conditions, the regulatory documents specify whether the drug is supported for short-term administration only or for long-term use.

Q: Does Genexin affect the results of common lab tests?

Official prescribing information includes specific warnings regarding the drug's potential for interference with certain laboratory diagnostic tests. This may result in a false-positive reading for particular substances being screened.

Q: How is Genexin eliminated from the body?

Regulatory documents detail the elimination pathway of the active ingredient and its active metabolite. This process primarily occurs through metabolism in the liver and subsequent excretion.

Q: How quickly is Genexin absorbed into the system?

Regulatory documents provide specific data on the drug's absorption kinetics. This data includes the time required to reach the maximum concentration (T max) in the bloodstream after the medicine is administered.

Q: Are the side effects of Genexin temporary, or can they be permanent?

Official safety information classifies adverse reactions by their frequency and severity in clinical studies. The resolution of common side effects is generally discussed in regulatory documents in the context of dose modification or changes to treatment.

Q: Can Genexin be taken if someone is scheduled for surgery?

Official prescribing information provides guidance on pre-operative management when Genexin is used. This guidance may advise caution or discontinuation before certain procedures, particularly due to the drug's documented effect on bleeding risk.

Q: What is the official classification of Genexin (e.g., Schedule IV, non-controlled)?

Regulatory agencies provide an official schedule classification (e.g., Schedule I–V or non-controlled) for medicines. This classification is determined based on the potential for abuse or dependence that the drug presents.

Q: Does Genexin interact with caffeine?

Regulatory documents detail known interactions with common CNS (Central Nervous System) stimulants. Official prescribing information addresses the presence or absence of a clinically significant interaction with caffeine based on regulatory review.

How should Genexin be stored and disposed of?

How to Store and Dispose of Genexin

Storage Requirements

Genexin (Venlafaxine) must be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its closed container and protected from excessive moisture and freezing to maintain product stability.

Storage Constraint Official Requirement
Temperature Controlled Room Temperature
Prohibited Environment Do not freeze; Protect from moisture
Safety Keep out of the reach of children

Disposal Instructions

Disposal must adhere to federal, state, and local requirements. Unused or expired Genexin should preferably be taken to an official drug take-back program. If a take-back option is unavailable, the medicine can be mixed with an unappealing substance, sealed in a container, and placed in the trash. It must not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Genexin found in:

A-Z Index: